Perspective Therapeutics, Inc. (CATX) vs Standard BioTools Inc. (LAB)
- Perspective Therapeutics, Inc. CATX 2.17 −7.26%
- Standard BioTools Inc. LAB 0.63 −4.55%
Perspective Therapeutics, Inc. and Standard BioTools Inc. are both Medical Devices companies. Perspective Therapeutics, Inc. and Standard BioTools Inc. are of similar size ($267.1M and $258.5M). Perspective Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Standard BioTools Inc. trades at 2.9×. Standard BioTools Inc. grew revenue faster over the last twelve months: 30.2% against −66.9%. Standard BioTools Inc. has the higher net margin (100.4% vs −28,468.0%) and the lower return on invested capital (−93.9% vs −88.4%). Across the 18 metrics below, Standard BioTools Inc. leads on 15 and Perspective Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | CATX | LAB | Medical Devices median |
|---|---|---|---|
| Gross margin | 100.00% | 50.49% | 56.01% |
| Operating margin | (30,619.07%) | (112.85%) | (15.03%) |
| Net margin | (28,467.97%) | 100.37% | (20.40%) |
| Free cash flow margin | (29,630.07%) | (97.61%) | (7.24%) |
| Return on equity | (39.50%) | 17.61% | (15.32%) |
| Return on assets | (33.14%) | 14.34% | (19.72%) |
| Return on invested capital | (88.41%) | (93.89%) | (10.33%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack